“Looking back over 2018, it is clear that the year was one of contrasts for biopharma companies. The medtech sector was fairly placid in comparison. For drug developers, areas of disappointment included the failure of acquisition activity to pick up, something many had hoped for at the beginning of the year. In the research sphere, the red hot immuno-oncology space was marked by clinical blow ups and lack of progress from experimental mechanisms. And for commercial-stage companies the downward pressure on drug pricing, and negative political rhetoric on the issue, continued apace. ”View the Report
Text and Images © Evaluate Ltd.